Press releases

Sachi's NanoligomerTM platform can deliver to the brain with systemic administration

Brain delivery of Nanoligomer using systemic administration What if you could deliver RNA therapeutics to the brain for high-precision...

Sachi selected for Creative Destruction Lab's 2022-2023 cohort

Sachi Bio has been selected to join the Creative Destruction Labs 2022-2023 cohort alongside 25 ground-breaking companies in the Advanced...

Sachi Bio receives NIH SBIR award

Sachi Bio wins NIH SBIR award to advance microbiome leads to treat auto-immune diseases. Difficult-to-treat autoimmune diseases that are...

Sachi Bio selected to join Endless Frontier Labs (EFL) 2022-23 cohort

Sachi Bio has been selected to join the Endless Frontier Labs 2022-2023 cohort alongside 25 ground-breaking companies in the Life...

Sachi Bio selected in the NASA I-Corps Program

Sachi Bio has been selected in the 2022 cohort of the NASA I-Corps program. The NASA I-Corps program enables small businesses, including...

Sachi Bio wins NASA Phase I SBIR award to advance drug-discovery on the ISS

May 26, 2022 Rapid, Low-Cost Drug-Discovery in Space In space exploration missions or space tourism outside the earth’s protective...

Sachi founders highlighted in “The Shift” column in the Timmerman Report

Out of the University, and in to Outer Space May 23rd, 2022 The Shift, by Lisa Suennen Lisa Suennen, is the managing founder of Venture...

Sachi Bio publishes on immunotherapy drug-development in Life Sciences in Space Research

Reversing radiation-induced immunosuppression using a new therapeutic modality May 11, 2022 Immune suppression poses significant health...

Ph: 720-361-2159

3000 Airport Drive, Unit 201,

Erie, CO 80516

Subscribe to Our Newsletter